688065 凯赛生物
已收盘 10-27 15:00:00
资讯
新帖
简况
10月27日凯赛生物现1笔折价16.85%的大宗交易 合计成交1200.03万元
证券之星 · 15分钟前
10月27日凯赛生物现1笔折价16.85%的大宗交易 合计成交1200.03万元
凯赛生物：生物法长链二元酸产品的毛利率主要受技术与工艺水平、原材料价格、产能利用率、产品市场价格等多重因素影响
证券之星 · 15:33
凯赛生物：生物法长链二元酸产品的毛利率主要受技术与工艺水平、原材料价格、产能利用率、产品市场价格等多重因素影响
凯赛生物：系列生物基聚酰胺销售额同比明显增长
证券之星 · 15:33
凯赛生物：系列生物基聚酰胺销售额同比明显增长
凯赛生物（688065）10月22日主力资金净卖出634.21万元
证券之星 · 10-23
凯赛生物（688065）10月22日主力资金净卖出634.21万元
股市必读：凯赛生物新发布《关于召开2026年第一次临时股东会的通知》
证券之星 · 10-22
股市必读：凯赛生物新发布《关于召开2026年第一次临时股东会的通知》
凯赛生物（688065）披露对外投资暨关联交易公告，10月21日股价下跌0.86%
证券之星 · 10-21
凯赛生物（688065）披露对外投资暨关联交易公告，10月21日股价下跌0.86%
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
证券之星 · 09-28
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
凯赛生物（688065）披露2025年员工持股计划预留份额分配公告，9月24日股价下跌2.49%
证券之星 · 09-24
凯赛生物（688065）披露2025年员工持股计划预留份额分配公告，9月24日股价下跌2.49%
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
证券之星 · 09-24
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
凯赛生物：目前合肥复材项目的部分生产线进入设备调试阶段
证券之星 · 09-21
凯赛生物：目前合肥复材项目的部分生产线进入设备调试阶段
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
证券之星 · 09-21
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
凯赛生物：公司与招商局集团的合作在稳步推进中
证券之星 · 09-21
凯赛生物：公司与招商局集团的合作在稳步推进中
凯赛生物：公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势
证券之星 · 09-21
凯赛生物：公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势
凯赛生物：2026年上半年生物基聚酰胺系列营收1.08亿元，同比增长63%
证券之星 · 09-21
凯赛生物：2026年上半年生物基聚酰胺系列营收1.08亿元，同比增长63%
破发股凯赛生物跌4.97% A股共募115亿IPO中信证券保荐
中金财经 · 09-14
破发股凯赛生物跌4.97% A股共募115亿IPO中信证券保荐
9月11日凯赛生物现3笔大宗交易 机构净卖出4368.65万元
证券之星 · 09-11
9月11日凯赛生物现3笔大宗交易 机构净卖出4368.65万元
【私募调研记录】勤远投资调研凯赛生物
证券之星 · 09-11
【私募调研记录】勤远投资调研凯赛生物
股市必读：凯赛生物新发布《中信证券股份有限公司关于上海凯赛生物技术股份有限公司2026年半年度持续督导跟踪报告》
证券之星 · 09-11
股市必读：凯赛生物新发布《中信证券股份有限公司关于上海凯赛生物技术股份有限公司2026年半年度持续督导跟踪报告》
凯赛生物：9月9日接受机构调研，兴业证券、浙商证券资管等多家机构参与
证券之星 · 09-10
凯赛生物：9月9日接受机构调研，兴业证券、浙商证券资管等多家机构参与
凯赛生物被调出科创50指数 A股共募115亿IPO中信证券保荐
中金财经 · 09-01
凯赛生物被调出科创50指数 A股共募115亿IPO中信证券保荐
加载更多
公司概况
公司名称：
上海凯赛生物技术股份有限公司
所属行业：
化学纤维制造业
上市日期：
2020-08-12
主营业务：
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC9-DC18）及其衍生产品、生物基戊二胺、系列生物基聚酰胺树脂及其改性产品、生物基连续纤维热塑型复合材料（Bio-PPACFRT）、生物基哌啶。
发行价格：
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":37.04,"timestamp":1793084400000,"preClose":38.49,"halted":0,"volume":3316578,"delay":0,"changeRate":-0.0377,"floatShares":583000000,"shares":721000000,"eps":0.8663,"marketStatus":"已收盘","change":-1.45,"latestTime":"10-27 15:00:00","open":38.69,"high":38.99,"low":37.04,"amount":126000000,"amplitude":0.0507,"askPrice":37.04,"askSize":276,"bidPrice":37.03,"bidSize":436,"shortable":0,"etf":0,"ttmEps":0.8663,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793151000000},"marketStatusCode":5,"adr":0,"adjPreClose":38.49,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793064600000,1793071800000],[1793077200000,1793084400000]],"highLimit":42.34,"lowLimit":34.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":1.5,"roa":"--","peRate":42.756551,"roe":"2.08%","epsLYR":0.82,"committee":0.129373,"marketValue":26717000000,"turnoverRate":0.0057,"status":1,"afterMarket":{"amount":47374.16,"volume":1279,"close":37.04,"buyVolume":0,"sellVolume":4171,"time":1793086437746,"indexStatus":"已收盘 10-27 15:30:00","preClose":38.49},"floatMarketCap":21608000000},"requestUrl":"/m/hq/s/688065","defaultTab":"news","newsList":[{"id":"2678164179","title":"10月27日凯赛生物现1笔折价16.85%的大宗交易 合计成交1200.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678164179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678164179?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:08","pubTimestamp":1793099329,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日凯赛生物发生大宗交易，交易数据如下：大宗交易成交价格30.8元，相对当日收盘价折价16.85%，成交38.96万股，成交金额1200.03万元，买方营业部为长城证券股份有限公司重庆新南路证券营业部，卖方营业部为长城证券股份有限公司重庆新南路证券营业部。近三个月该股共发生4笔大宗交易，合计成交2.15万手，折价成交1笔。截至2026年10月27日收盘，凯赛生物报收于37.04元，下跌3.77%，换手率0.57%，成交量3.32万手，成交额1.26亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700036426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678125597","title":"凯赛生物：生物法长链二元酸产品的毛利率主要受技术与工艺水平、原材料价格、产能利用率、产品市场价格等多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2678125597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678125597?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:33","pubTimestamp":1793086429,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物10月27日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700024249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678255711","title":"凯赛生物：系列生物基聚酰胺销售额同比明显增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2678255711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678255711?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:33","pubTimestamp":1793086428,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物10月27日在投资者关系平台上答复投资者关心的问题。结合系列生物基聚酰胺及其复合材料产品的综合优势特点，公司正持续推进产品、客户开发，加大商业化推广力度，并通过技术迭代、工艺优化、规模化生产、产业链协同等多种方式推进降本增效工作。今年上半年，公司系列生物基聚酰胺销售额同比明显增长，长链聚酰胺实现规模化销售，毛利率亦呈现改善趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700024246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677918102","title":"凯赛生物（688065）10月22日主力资金净卖出634.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677918102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677918102?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:22","pubTimestamp":1792714944,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月22日收盘，凯赛生物报收于36.62元，下跌0.25%，换手率0.41%，成交量2.39万手，成交额8794.08万元。近5日资金流向一览见下表：凯赛生物融资融券信息显示，融资方面，当日融资买入537.48万元，融资偿还670.65万元，融资净偿还133.17万元。凯赛生物主营业务：以合成生物学等学科为基础,利用生物制造技术,从事新型生物基材料的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300007492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677609298","title":"股市必读：凯赛生物新发布《关于召开2026年第一次临时股东会的通知》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677609298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677609298?lang=zh_cn&edition=full","pubTime":"2026-10-22 02:47","pubTimestamp":1792608429,"startTime":"0","endTime":"0","summary":"公司公告汇总：公司将于2026年11月9日召开2026年第一次临时股东大会，审议《关于对外投资暨关联交易的议案》，股权登记日为2026年11月2日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200001663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677670482","title":"凯赛生物（688065）披露对外投资暨关联交易公告，10月21日股价下跌0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677670482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677670482?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:34","pubTimestamp":1792593260,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘，凯赛生物报收于36.71元，较前一交易日下跌0.86%，最新总市值为264.79亿元。该股当日开盘37.12元，最高37.3元，最低36.66元，成交额达6667.65万元，换手率为0.31%。近日，上海凯赛生物技术股份有限公司发布《关于对外投资暨关联交易的公告》。本次投资构成与关联方共同投资，尚需公司股东会批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100041570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401147","title":"股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401147?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:45","pubTimestamp":1790538314,"startTime":"0","endTime":"0","summary":"关于2025年员工持股计划预留份额分配的公告上海凯赛生物技术股份有限公司同意将15.00万股预留份额授予不超过54名激励对象，认购价格为25.08元/股；预留份额分配后，员工持股计划所持股票总数不超过公司股本总额的10%，单个持有人对应股票总数不超过公司股本总额的1%；标的股票自过户至员工持股计划名下之日起12个月后分两批解锁，每批解锁50%，解锁需满足公司、部门及个人层面业绩考核要求；该事项无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469419","title":"凯赛生物（688065）披露2025年员工持股计划预留份额分配公告，9月24日股价下跌2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469419","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469419?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:48","pubTimestamp":1790243336,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，凯赛生物报收于38.34元，较前一交易日下跌2.49%，最新总市值为276.54亿元。凯赛生物近日披露《关于2025年员工持股计划预留份额分配的公告》。公告显示，公司于2026年9月23日召开相关会议，审议通过《关于2025年员工持股计划预留份额分配的议案》，同意将15.00万股预留份额授予不超过54名激励对象，认购价格为25.08元/股。标的股票自过户至员工持股计划名下之日起12个月后分两批解锁，每批解锁50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400031254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438580","title":"股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669438580?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:10","pubTimestamp":1790183420,"startTime":"0","endTime":"0","summary":"关于非全资控股子公司之间提供担保额度的公告上海凯赛生物技术股份有限公司授权其在总额不超过20亿元额度内向非全资控股子公司提供担保，被担保人为凯赛（太原）生物材料有限公司和凯赛（太原）生物科技有限公司，二者均为公司合并报表范围内控股子公司，资产负债率均未超过70%；本次担保无需提交股东大会审议，额度可在两家子公司间调剂；截至公告日，公司及其控股子公司对外担保总额为3亿元，无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400001915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669915551","title":"凯赛生物：目前合肥复材项目的部分生产线进入设备调试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669915551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669915551?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976218,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好，关注到公司合肥年产4万吨碳纤维增强生物基聚酰胺复合材料项目计划今年年内建成。请问目前项目进度如何？能否按期投产？投产后主要面向哪些行业和客户？谢谢！凯赛生物回复：尊敬的投资者，您好。目前合肥复材项目的部分生产线进入设备调试阶段，产品下游涵盖新能源、建筑、物流等行业。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669553961","title":"凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2669553961","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669553961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976217,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好，太原年产50万吨戊二胺和90万吨聚酰胺项目之前公告延期到了2027年底。公司年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中，具体进展请参考公司公告。山西科创城投作为公司的早期外部投资者，其减持系基于自身资金需求，不影响公司与园区的项目建设。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669553691","title":"凯赛生物：公司与招商局集团的合作在稳步推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2669553691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669553691?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976216,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物09月21日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669578155","title":"凯赛生物：公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2669578155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669578155?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976212,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司介绍配套长安凯程无人物流车的复合地板具有不少实用的性能。问题一：该地板能同时提供给其他客户吗？问题二：量产后，与传统材料相比，性价比情况如何？或者说后续降本空间大吗？凯赛生物回复：尊敬的投资者，您好。公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势，可以推广应用于其他主机厂的类似场景。目前，公司商务团队正在积极拓展客户，扩大产品应用范围。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669515552","title":"凯赛生物：2026年上半年生物基聚酰胺系列营收1.08亿元，同比增长63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669515552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669515552?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976211,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司上市后投入的生物基聚酰胺产品，10万吨自投产后毛利率下滑到负1X%，销量年年下滑。2026年上半年，公司生物基聚酰胺系列实现营业收入1.08亿元，同比增长63%,毛利率0.57%。目前，公司的系列生物基聚酰胺及其复合材料产品处于商业化推广阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656273","title":"破发股凯赛生物跌4.97% A股共募115亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656273","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667656273?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:01","pubTimestamp":1789372863,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 凯赛生物 今日收报37.88元，跌幅4.97%。该股目前处于破发状态。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物上述2次募集资金合计114.87亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260914/32369019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2580892789.USD","LU1997245177.USD","83188","83130","BK0208","159982","KCE","LU1064130708.USD","LU1997245094.SGD","LU2148510915.USD","LU1255011170.USD","LU1146622755.USD","06030","02846","BK0196","LU2495084118.USD","FRHC","IPOS","LU1820825898.SGD","LU0405327494.USD","LU1064131003.USD","LU2289578879.USD","REDS","LU1720050803.USD","BK0183","02827","07233","LU0405327148.USD","LU1794554557.SGD","LU1997244956.HKD","03188","BK1516","BK1564","LU1655091616.SGD","BK0028","BK1147","LU2580892862.HKD","BK1521","82846","BK0188","688065","BK4127","LU1328615791.USD","LU1580142542.USD","600030","LU1781817850.SGD","399300","BK0012","03130","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666280765","title":"9月11日凯赛生物现3笔大宗交易 机构净卖出4368.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666280765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666280765?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:38","pubTimestamp":1789119511,"startTime":"0","endTime":"0","summary":"证券之星消息，9月11日凯赛生物发生大宗交易，交易数据如下：近三个月该股共发生3笔大宗交易，合计成交1.76万手。该股近期无解禁股上市。截至2026年9月11日收盘，凯赛生物(688065)报收于39.86元，上涨0.66%，换手率2.06%，成交量12.04万手，成交额4.77亿元。该股近半年内有股东持股变动，合计净减持150.0万股，股东增减持明细如下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为60.18。本文数据来源于上海证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100038442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751121","title":"【私募调研记录】勤远投资调研凯赛生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666751121?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:04","pubTimestamp":1789085089,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月10日披露的机构调研信息，知名私募勤远投资近期对1家上市公司进行了调研，相关名单如下：1）凯赛生物 调研纪要：2026年上半年，公司生物基聚酰胺系列实现营业收入1.08亿元，同比增长63%，毛利率0.57%。机构简介：上海勤远私募基金管理中心于2013年11月份成立于上海浦东，投资团队成员拥有良好的教育背景，以及丰富的实业创业和证券从业经验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026091100013906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597420","title":"股市必读：凯赛生物新发布《中信证券股份有限公司关于上海凯赛生物技术股份有限公司2026年半年度持续督导跟踪报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597420","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666597420?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:17","pubTimestamp":1789060628,"startTime":"0","endTime":"0","summary":"招商证券股份有限公司关于上海凯赛生物技术股份有限公司2026年持续督导定期现场检查报告招商证券现场检查确认公司治理结构健全，信息披露制度有效执行，独立性良好，无关联方资金占用；募集资金使用合规；未发现关联交易、对外担保和重大对外投资违规情形；公司经营正常，业务模式未发生重大变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","LU2580892862.HKD","LU1820825898.SGD","LU1720050803.USD","LU1328615791.USD","BK1564","LU1255011170.USD","LU2495084118.USD","688065","LU1064131003.USD","BK1521","BK0028","BK0208","LU1997245094.SGD","LU0405327148.USD","LU1146622755.USD","LU1064130708.USD","600030","BK0276","BK0188","LU0405327494.USD","LU2580892789.USD","LU1781817850.SGD","LU1997244956.HKD","BK1147","BK0196","06030","LU1794554557.SGD","LU2148510915.USD","BK1516","LU1997245177.USD","BK0183","LU1580142542.USD","LU1655091616.SGD","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666759646","title":"凯赛生物：9月9日接受机构调研，兴业证券、浙商证券资管等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2666759646","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666759646?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:10","pubTimestamp":1789045848,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月10日凯赛生物发布公告称公司于2026年9月9日接受机构调研，兴业证券、浙商证券资管、招银理财、勤远投资、银河证券参与。未来公司将继续围绕长链二元酸下游衍生物及新材料方向，审慎评估并购及投资机会。该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为60.18。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000040703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208","BK0276","601878","BK0012","601377","BK0183","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664880314","title":"凯赛生物被调出科创50指数 A股共募115亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2664880314","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664880314?lang=zh_cn&edition=full","pubTime":"2026-09-01 11:34","pubTimestamp":1788233643,"startTime":"0","endTime":"0","summary":"中国经济网北京9月1日讯 上海证券交易所与中证指数有限公司披露将调整科创50等指数样本，于2026年9月11日收市后生效，其中科创50指数更换5只样本，凯赛生物 被调出。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 凯赛生物上述2次募集资金合计114.87亿元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/01/20260901607569.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/01/20260901607569.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260901/32356125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1328615791.USD","LU1997245094.SGD","LU1146622755.USD","03188","LU1064130708.USD","REDS","LU1997244956.HKD","07233","LU1781817850.SGD","KCE","LU1794554557.SGD","LU1820825898.SGD","LU1720050803.USD","IPOS","02827","82846","83130","BK4127","LU1064131003.USD","BK1521","LU2580892789.USD","159371","03130","FRHC","BK0208","688065","BK0276","LU2495084118.USD","BK0012","BK0028","LU0405327494.USD","LU1255011170.USD","02846","399300","BK1564","LU2289578879.USD","LU1655091616.SGD","BK0188","83188","LU1997245177.USD","BK1516","LU1580142542.USD","06030","LU0405327148.USD","LU2580892862.HKD","600030","BK0183","LU2148510915.USD","BK0196","159982"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793100204758,"stockEarnings":[{"period":"1week","weight":0.0493},{"period":"1month","weight":0.0039},{"period":"3month","weight":-0.1262},{"period":"6month","weight":-0.1855},{"period":"1year","weight":-0.198},{"period":"ytd","weight":-0.2192}],"compareEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":-0.0491},{"period":"3month","weight":-0.0304},{"period":"6month","weight":-0.0998},{"period":"1year","weight":-0.064},{"period":"ytd","weight":-0.0684}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"19123人(较上一季度增加3.24%)","perCapita":"30506股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC9-DC18）及其衍生产品、生物基戊二胺、系列生物基聚酰胺树脂及其改性产品、生物基连续纤维热塑型复合材料（Bio-PPACFRT）、生物基哌啶。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}